Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
By B. Routy, E. Le Chatelier, L. Derosa, Connie P. M. Duong, M. Alou, Romain Daillère, Aurélie Fluckiger, M. Messaoudene, C. Rauber, M. Roberti and 38 more. Science, 2018
4,955 citations recorded by the source corpus.
Subfields: Immunology, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/075147bad63d8e465892f729f2876c6ecae89e84
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Molecular Biology
In Oncology
Citations in the corpus
- Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. (2020, background): “However, manipulation of diets ultimately modulates the gut microbiome which in turn affects tumor and immune metabolism and can even play a significant role in modulating tumor responses to immunotherapy across multiple cancer types (Gopalakrishnan et al., 2018; Matson et al., 2018; Routy et al., 2”
- Human gut microbiota/microbiome in health and diseases: a review (2020, background): “These cytokines can cross the BBB and activate neurons that altered neurological function and resulting in a change in mood and behavior (Sampson and Mazmanian 2015).”
- Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022, neutral): “that of immunotherapy-resistant populations [311, 312].”
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic (2018, background): “inflamed gene expression profile (GEP) [26], immune gene expression signatures [27, 28], as well as description of the microbiome [29-31] also represent emerging predictive”